Your browser doesn't support javascript.
loading
Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms.
Handlos Grauslund, Jacob; Holmström, Morten Orebo; Jørgensen, Nicolai Grønne; Klausen, Uffe; Weis-Banke, Stine Emilie; El Fassi, Daniel; Schöllkopf, Claudia; Clausen, Mette Borg; Gjerdrum, Lise Mette Rahbek; Breinholt, Marie Fredslund; Kjeldsen, Julie Westerlin; Hansen, Morten; Koschmieder, Steffen; Chatain, Nicolas; Novotny, Guy Wayne; Petersen, Jesper; Kjær, Lasse; Skov, Vibe; Met, Özcan; Svane, Inge Marie; Hasselbalch, Hans Carl; Andersen, Mads Hald.
Afiliación
  • Handlos Grauslund J; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • Holmström MO; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • Jørgensen NG; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • Klausen U; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • Weis-Banke SE; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • El Fassi D; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark.
  • Schöllkopf C; Department of Medicine, Copenhagen University, Copenhagen, Denmark.
  • Clausen MB; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark.
  • Gjerdrum LMR; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark.
  • Breinholt MF; Department of Pathology, Zealand University Hospital, Roskilde, Denmark.
  • Kjeldsen JW; Department of Pathology, Copenhagen University Hospital, Herlev, Denmark.
  • Hansen M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • Koschmieder S; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • Chatain N; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
  • Novotny GW; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
  • Petersen J; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark.
  • Kjær L; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark.
  • Skov V; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
  • Met Ö; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
  • Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • Hasselbalch HC; Institute for Immunology and Microbiology, Copenhagen University, Copenhagen, Denmark.
  • Andersen MH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Front Oncol ; 11: 637420, 2021.
Article en En | MEDLINE | ID: mdl-33718228
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2021 Tipo del documento: Article País de afiliación: Dinamarca
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2021 Tipo del documento: Article País de afiliación: Dinamarca